Investment Trust Insider on Supermarket Income REIT James Carthew: Supermarket Inc should go down main aisle Last summer Supermarket Income (SUPR) presented investors with a new alternative in their search for predictable, inflation-linked yields. Since then the real estate investment trust (Reit) has announced quarterly dividends of 1.375p, equating to a 5.5% yield on its […]
Juridica left with seven cases – During 2017, Juridica’s NAV per share dropped by US$0.0977 per share from US$0.2541 per share at 31 December 2016 to US$0.1563 per share at 31 December 2017. mostly this relates to the payment of dividends amounting to US$11.9 million (US$0.1074 per share) but it also made a profit during 2017 of US$1.1 million (US$0.0097 per […]
Fidelity Japanese Values delivered positive outperformance in its annual results for the year ended 31 December 2017, resulting in a NAV total return of +34.1%. The Russell Nomura Mid/Small Cap Index gained 17.5% in sterling terms over the same time period. The share price rose by 49.3% and as a result the discount to NAV narrowed […]
Bias towards transparent companies behind Pacific Assets’ underperformance – Pacific Assets Trust (PAC) delivered an NAV per share total return of +12.8% in the year to 31 January 2018. It lagged the Benchmark MSCI All Country Asia ex Japan Index’s return of +27.0%. The average share price discount to the NAV per share during the year was 2.4% which […]
Trust favourite Alnylam sees shares tank on competitor success US RNAi therapeutic specialist Alnylam Pharmaceuticals (Nasdaq:ALNY) has seen its shares fall by 22% over the long Easter weekend, principally on news of a surprise positive clinical trial result for a potential competitor to its lead product patisiran, which has been developed initially for hereditary transthyretin-mediated amyloidosis […]
Above average number of natural disasters impact on Blue Capital – the NAV of Blue Capital Alternative Income (BCAI) was hit by a higher than average occurrence of natural disasters during the year to 31 December 2017. please see our note on Blue Capital Alternative Income published on 13 February entitled “Wind blown but still standing” Blue Capital Alternative […]
HBM Healthcare to benefit from Homology Medicines IPO Swiss-listed HBM Healthcare (HBMN) is set to receive a modest boost to its NAV following the US initial public offering last week of Homology Medicines (Nasdaq: FIXX), a US gene editing/gene therapy company developing treatments for rare disease. Homology raised a total of $165.6m from an offering of 10.35m shares at $16.00 […]
WPCT gets surprise boost up trust leaguetable from Prothena deal An unexpected recovery in Woodford Patient Capital Trust (WPCT)’s share price last month on the back of the collaboration signed between investee Prothena (NASDAQ:PRTA) and Celgene (NASDAQ:CELG), has made the struggling investment trust the surprise top performer among the sector specialist funds in March, albeit amid […]
3i Infrastructure makes investment in Attero – 3i Infrastructure will invest €201m to acquire a 50% stake in Attero, one of the largest waste treatment and disposal companies in the Netherlands. 3i Infrastructure will invest alongside DWS’s infrastructure investment business (formerly Deutsche Asset Management) to acquire Attero from Waterland, a Dutch private equity fund. 3i […]
‘Experienced. Disciplined. Determined. All you want from a hero.’ – Merchants Trust outperformed the All-Share, its benchmark index over the year to the end of January 2018. Its NAV total return was +14.5% with debt at market value, outperforming the benchmark total return of +11.3%. This investment return placed the company 6 out of 25 funds in […]
